Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Everolimus in Relapsed/Refractory Marginal Zone B-cell Lymphoma
NCT01164267Phase 2Completed
- Sponsor
- International Extranodal Lymphoma Study Group
- Start
- Mar 2010
- Primary completion
- Dec 2012
- Modality
- Small Molecules
- Countries
- 3
01
Overview
A Phase 2 trial of everolimus in marginal zone B-cell lymphoma (MZL), sponsored by International Extranodal Lymphoma Study Group. Started Mar 2010; status: completed.
02
Drugs
everolimus
03
Conditions
marginal zone B-cell lymphoma (MZL)
Beyond the preview
Go deeper on NCT01164267.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01164267.